ABSTRACT
COVID-19, a pandemic caused by severe acute respiratory syndrome (SARS) corona virus-2 has been a worldwide challenge for the entire mankind. However, a safe and efficacious vaccine would be clinically valuable to reduce the risks of COVID-19. In this study, we aimed to assess the seroprevalence of the Neutralizing IgG Antibodies six months after completion of both the doses of Covishield Vaccination (ChAdox1 nCoV-19) and compare it with the IgG titres one month after the first dose and one month after the second dose of the vaccine respectively. The efficacy, safety and comorbidities related to the vaccine were also assessed at different time intervals. The levels of IgG antibodies were estimated in 72 subjects from the Teerthanker Mahaveer Medical College & Research Centre (who turned up after six months of the complete regimen of Covishield Vaccination) using the Enzyme-Linked Immunosorbent Assay (ELISA) Technique. A highly significant increase (p= 0.00) in the neutralizing Antibodies titre was seen in fully vaccinated individuals post six months when compared to the titres of post one month of 1st & 2nddoses. It can therefore be concluded that (ChAdox1 nCoV-19) Covishield Vaccination if administered in full regimen has both acceptable efficacies as well as safety profile. Hence, a complete vaccine regimen may prove as an effective strategy against COVID-19 and consequent minimization of long-term morbid effects. © 2022 International Journal of Health Sciences.
ABSTRACT
Coronavirus outbreak has challenged the medical, public health infrastructure and economic status of nearly all countries across the World. The main issue of concern with SARS-CoV-2 has been the high infectivity rate and the high mortality rate especially, observed during the wave 2 of COVID-19. The symptoms associated with SARS-CoV-2 are often misleading with influenza and another respiratory tract seasonal viral infection as, majority of the patients report common constitutional symptoms. Hence, correct diagnosis for COVID-19 may play a key role in early detection, management and curtailment in the transmission rate.Therefore, apart from limiting this outbreak, efforts need to be made to plan comprehensive and stringent measures to develop diagnostic tools to prevent future outbreaks of this zoonotic disease. The present manuscript provides a detailed description of various indices and parameters which are currently being used for easier, rapid, accurate diagnosis, medical managementand prognosis assessment of COVID-19 patients in various stages of the disease.
ABSTRACT
Background: Covid-19, a zoonotic disease caused by Severe Acute Respiratory Syndrome Coronavirus - 2 (SARSCov-2) has emerged as a worldwide infection and has been declared pandemic since March, 2020, by WHO. This has brought about tremendous burden on the health care system of not only the developing or the third world countries but also that of prosperous counties of the world. The recent Covid-19 pandemic has pushed the worldwide scientific and medical community to find a solution with the help of vaccines to control SARS-CoV-2 pandemic. An effective vaccine is one which leads to synthesis of IgG antibodies against SARS-CoV-2, thus aiding the control and decline of the pandemic. Aim: This study aims to evaluate the antibody titres post 1st dose and post 2nd dose Covishield vaccination and reveals the safety and efficacy of ChAdOx1 nCoV-19(Recombinant) Covishield vaccine. Methodology: The levels of IgG antibodies were estimated in 215 subjects (both normal subjects and Covid-19 positive subjects) using Enzyme Linked Immunosorbent Assay (ELISA) Technique. Results: Two hundred & fifteen subjects from Teerthanker Mahaveer Hospital of Moradabad (western Uttar Pradesh) were enrolled for the study. The participants were divided into two different groups. Group I comprised of 215 subjects who received 1st dose of the Covishield vaccine. Group II comprised of 101 subjects who received both the doses of the ChAdOx1 nCoV-19(Recombinant) Covishield vaccine. Levels of IgG were analysed 28 days post 1st dose of ChAdOx1 nCoV-19(Recombinant) Covishield vaccine and post 2 nd dose of ChAdOx1 nCoV-19(Recombinant) Covishield vaccination. After testing serologically for neutralising IgG antibodies, the titre was found to be below the threshold level of 1.1 in 67.40% of the subjects in the study group 1, whereas 32.60% (n=70) were found to be in the seroprotective range (i.e IgG titre > 1.1). Out of the total 101 participants who took both the doses, 39 participants (38.6%) were found to be in the seroprotective range (i.e IgG titre > 1.1). Conclusion: The two doses of Covishield vaccination (4 weeks interval) given to subjects resulted in increase in IgG antibody titre (Neutralising Antibodies) against both spike protein and nucleocapsid protein after 1st dose and 2nd dose and that single dose may suffice for seroprotection in subjects with previous history of COVID-19 who had recovered from the disease.